In the treatment of refractory inflammatory breast cancer, Lapatinib also showed a good effect. EGF103009 The study reports on preliminary results. 34 cases of inflammatory breast cancer, 17 cases of molecular targets for the determination of 11 patients with HER2 over-expression (A group), 6 cases of HER1-positive and HER2-negative (B group), results showed that A group efficiency 72%, B was no case of effective.
Lapatinib is currently on a series of Phase III studies are under way, including the Lapatinib combined Taxol, joint Xeloda, joint letrozole, while a joint Herceptin and Taxol, as well as single-agent treatment of brain metastasis. Believed that with more clinical research report on the results, in the Herceptin, would provide the patients with HER2 overexpressing breast cancer treatment was again brought new surprises.
2 angiogenesis inhibitors
Angiogenesis is a tumor, proliferation and invasion of the necessary conditions, vascular endothelial growth factor (VEGF) that affect the formation of new blood vessels the most important factor. Bevacizumab (Avastin) is a recombinant human monoclonal antibody with endogenous competitive binding of VEGF to VEGF receptors, so that endogenous VEGF biological activity fail to inhibit endothelial cell mitosis, increasing vascular permeability, reducing the formation of new blood vessels, and ultimately achieving the role of inhibiting tumor growth.
E2100 study is a comparative bevacizumab combined with single-agent Taxol Taxol, first-line treatment of advanced breast cancer Phase III clinical study. Study, treatment with weekly Taxol treatment (90mg/m2 No. 1,8,15 days), bevacizumab 10mg/Kg, every 2 weeks one time, 4 weeks of a cycle. Total income group of 715 cases of patients, combination therapy improved the efficiency (28.2% VS 14.2% P <0.0001), longer progression-free survival time (10.97 months VS 6.11 months, P <0.001). Currently, the U.S. NCCN treatment guidelines for the treatment programs have been included.
3 other molecular targets
In the field of breast cancer treatment, there are other targets of the drug being investigated. As for the RAS family, farnesyltransferase inhibitors, ubiquitin – proteasome pathway and so on. These related drugs is still I, II clinical study stage. As human tumor occurrence and development of the gradual in-depth understanding of the molecular mechanism is bound to have more targets for different elements of drugs come out. Coupled with pharmacogenomics research results rich in cancer treatment will ultimately achieve “true individual treatment”, that is, according to each patient’s genetic status of medication, so that patients benefit most, while facing minimal side effects.
